
SMS Pharmaceuticals Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
No
0 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- SMS Pharmaceuticals anticipates maintaining steady growth with a 10-15% year-on-year increase in revenues.
- The company expects to achieve all-time high sales in the next 2-3 financial years if current trends continue.
- Growth drivers include key segments like ARV, Ibuprofen, anti-diabetic, anti-ulcer, anti-migraine, and anti-inflammatory APIs.
- Ibuprofen volumes have shown consistent month-on-month growth; capacity utilization is targeted to increase to about 75% by FY25.
- The ARV segment, after some delays, is expected to sustain steady sales with good demand visibility beyond March.
- The company is also exploring new product launches and niche segments with higher realizations.
- Backward integration and cost optimization measures are expected to enhance margins and support growth.
- Expansion into contract development and manufacturing opportunities is under consideration but not yet finalized.
See what SMS Pharmaceuticals management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any major capital expenditure (capex) expansion or new fundraising through debt or equity currently planned.
- The company is focusing on consolidating its recent major expansion, especially in Ibuprofen capacity, before considering further capacity increases.
- Regular small capex expansions are ongoing, but no significant fundraising activities have been indicated.
- The management emphasizes consolidation and organic growth rather than immediate fundraising.
- Future plans may include product and capacity expansions but no specifics about debt or equity raising were provided in the call.
See what SMS Pharmaceuticals management said on order book — free account, 30 seconds.
Capex plans
No- No major capex expansions are planned in the near term.
- The company has recently completed a significant expansion of Ibuprofen capacity.
- Current focus is on consolidating operations post the recent capacity expansion.
- Small, regular capex investments will continue as part of routine operations.
- Future capacity utilization target is around 75% by FY25, which may guide subsequent expansion decisions.
- Product lineup expansion is ongoing with a good pipeline of products approaching commercialization.
- The company is exploring contract development and manufacturing (CDMO) opportunities selectively but no finalized investments yet.
Track SMS Pharmaceuticals — get its next earnings analysis in your feed
How does SMS Pharmaceuticals rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does SMS Pharmaceuticals rank in Pharmaceuticals & Biotechnology?
Compare SMS Pharmaceuticals against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.
Continue your research
What SMS Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem